Overcoming Bioavailability Challenges

Published: 5-Sep-2013

3 October 2013

Event

Royal Society of Chemistry, London, UK


At this one-day event, leading experts on drug development and delivery from across industry and academia, including the University of Bath, Catalent Pharma Solutions, BASF, 3M and Formac Pharmaceuticals, will share the most effective and innovative approaches and technologies for bioavailability solutions.

Organiser: Catalent Applied Drug Delivery Institute

www.drugdeliveryinstitute.com

Trending Articles

  1. CPhI North America 7-9 May 2024 | Exhibition | Pennsylvania, US
  2. Cleanroom Conference UK 22–23 May 2024 | Exhibition | Birmingham, UK
  3. ASGCT Annual Meeting 2024 7-11 May, 2024 | Meeting | Portland, OR
  4. CPhI South East Asia 2024 10-12 July 2024 | Exhibition and Conference | Bangkok, Thailand
  5. Lounges 23-25 April 2024 | Conference | Messe Karlsruhe, Germany

You may also like

Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Manufacturing

Catalent completes $2.2 million expansion to clinical supply facility

The site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services
Drug Delivery

Catalent opens commercial-scale plasmid DNA facility in Belgium

The state-of-the-art facility contains over 12,000 sqft of development and manufacturing space across multiple cleanrooms
Drug Delivery

Catalent to provide supply chain oversight with Case Management Service

It is set to coordinate the scheduling of material collection, the manufacturing slot for the therapy, arrange shipments and continuously manage its status
Ingredients

Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment

Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology
Subscribe now